Table 3.
Scores | dpc | Group 1 | Group 2 | Group 3 |
---|---|---|---|---|
Observed clinical score | 0 | 0.0 ± 0.00 | 0.5 ± 0.71 | 0.8 ± 0.45 |
1 | 0.0 ± 0.00 | 1.0 ± 1.41 | 0.8 ± 1.10 | |
2 | 0.0 ± 0.00 | 0.5 ± 0.71 | 1.0 ± 1.22 | |
3 | 0.7 ± 0.58 | 2.0 ± 2.83 | 1.0 ± 1.00 | |
4 | 1.7 ± 0.58 | 4.5 ± 0.71* | 1.2 ± 0.84* | |
5 | 2.67 ± 2.08 | 9.5 ± 0.71* | 3.4 ± 1.95* | |
6 | 10.33 ± 3.51 | na | 6.4 ± 3.58 | |
7 | 25.67 ± 10.97 | na | 15.2 ± 9.52 | |
8 | na | na | 28.8 ± 7.16 | |
Gross pathological score | 5–8 | 29.7 ± 9.87 | 31.5 ± 7.78 | 18.6 ± 13.94 |
Histopathological score | 5–8 | 62.2 ± 10.77 | 66 ± 9.90 | 57.9 ± 19.32 |
Mean ± standard deviation (SD); dpc = days post challenge; na = no surviving animals. Clinical and pathological scoring details are provided in supplementary Tables S1 and S2. Significance found between Groups 2 and 3 clinical scores at days 4 and 5 (*; p-values of 0.004 and 0.009, respectively). Statistical significance was determined by multiple comparison t test using the Holm-Sidak method, with alpha = 5.000%, and each row analyzed individually, without assuming a consistent SD.